BUBerat Uğuz

Berat Uğuz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Berat Uğuz has a total of 217 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association between PRECISE-DAPT score and clinical outcomes: a subgroup analysis of the DAPT-TR registry

    by Berat Uğuz, Ahmet Öz, Ömer Kertmen, İlYas Çetin, Lütfü Bekar, Ferit Büyük, Serkan Asil, Mehmet Cansel, Hakan Taşolar, Mehdi Zoghi

    This study aimed to evaluate whether a PRECISE-DAPT score ≥ 25 identifies a high-risk phenotype associated with adverse ischemic and bleeding outcomes, hospitalisation, and mortality among patients treated with fixed-dose acetylsalicylic acid and clopidogrel. We conducted a prespecified subgroup analysis of the DAPT-TR registry, a prospective, multicentre observational cohort including 1,500 patients who were initiated on fixed-dose combination dual antiplatelet therapy (aspirin 75 mg/day plus clopidogrel 75 mg/day) for the treatment of acute and stable coronary artery disease. Patients were stratified according to PRECISE-DAPT score categories (≥ 25 vs < 25). Six-month clinical outcomes, including all-cause and cardiovascular hospitalisation, myocardial infarction, stent thrombosis, BARC type 1 bleeding, all-cause mortality, cardiovascular mortality, and stroke, were compared between groups. Multivariable logistic regression analysis was performed to evaluate independent associations between PRECISE-DAPT score categories and clinical outcomes. Of 1,500 patients, 344 (22.9%) had a PRECISE-DAPT score ≥ 25. Compared with patients with a PRECISE-DAPT score < 25, those with a PRECISE-DAPT score ≥ 25 were older (mean age 71.9 vs. 60.8 years; p < 0.001), more frequently female, and had significantly more comorbidities and reduced LVEF. At 6 months, patients with a PRECISE-DAPT score ≥ 25 experienced higher rates of all-cause hospitalisation (19.5% vs. 10.9%; p < 0.001), cardiovascular hospitalisation (11.6% vs. 6.7%; p = 0.003), stent thrombosis (2.6% vs. 1.0%; p = 0.029), and BARC type 1 bleeding (7.5% vs. 2.2%; p < 0.001). All-cause mortality (1.7% vs. 0.2%; p = 0.003) and cardiovascular mortality (1.2% vs. 0.1%; p = 0.011) were also significantly higher. After adjustment, a PRECISE-DAPT score ≥ 25 remained independently associated with mortality (OR: 3.8; 95% CI: 1.2-12.1) and hospitalisation (OR: 2.1; 95% CI: 1.5-3.1). A PRECISE-DAPT score ≥ 25 delineates a clinically vulnerable subgroup with elevated ischemic, haemorrhagic, and mortality risks, even under uniform fixed-dose DAPT. These findings suggest that the PRECISE-DAPT score may serve as a multidimensional prognostic tool beyond bleeding risk stratification.

  • Open Access

    Persisting Sex Discrepancies in Short-Term Outcomes of Patients with ST-Segment Myocardial Infarction: Results of the ISACS-STEMI COVID-19 Registry

    by Giuseppe De Luca, Stephane Manzo-Silberman, Filippo Zilio, Magdy Algowhary, Berat Uguz, Dinaldo C. Oliveira, Vladimir Ganyukov, Zan Zimbakov, Miha Cercek, Lisette Okkels Jensen, et al.

    Background. Despite technological innovations and improvements in stents and devices, sex-related discrepancies are still reported in the outcomes after ST-segment elevation myocardial infarction (STEMI), depending on biological and sex-specific pathophysiological differences, which have not been completely understood. The aim of the present study was to provide real-world data on the prognostic role of sex among patients with STEMI, enclosed into a recent up-to-date international registry. Methods. The ISACS-STEMI COVID-19 is a large-scale retrospective registry, including STEMI patients treated with mechanical reperfusion between 1 March and 30 June, 2019 and 2020. Patients, treated in 109 centers across Europe, Latin America, Southeast Asia, and North Africa, were grouped according to sex. Primary endpoint: In-hospital mortality; secondary endpoints: Time delay, 30-day mortality, and postprocedural Thrombolysis In Myocardial Infarction (TIMI) 3 flow. Results. We included 16,083 patients, 24.3% females (54.3% hospitalized in 2019, 45.7% in 2020). Women with STEMI were older, more often diabetic and hypertensive (p < 0.001), with a higher prevalence of hypercholesterolemia (p = 0.02), longer ischemia time (p = 0.01), ambulance referral (p = 0.03) and cardiogenic shock at presentation (p = 0.05), but less frequently smokers, with a previous cardiovascular event (p < 0.001) or anterior STEMI (p = 0.03) as compared to males. Preprocedural TIMI 0 flow, multivessel disease, need for thrombectomy (p < 0.001 and p = 0.001, respectively), use of Glycoprotein IIbIIIa inhibitors or cangrelor, radial access and implantation of drug-eluting stents (p < 0.001, p < 0.001 and p = 0.001, respectively) were also more common in men. Impaired postprocedural epicardial reperfusion (TIMI flow 0–2) was observed more frequently in females as compared to males (10% vs. 7.2%; adjusted OR [95% CI] = 1.30 [1.13–1.49], p = 0.01). In-hospital mortality was 5.8%, significantly higher among women (8.3% vs. 5%, p < 0.001, adjusted HR [95% CI] = 1.26 [1.06–1.5], p = 0.01). Similar data were observed for 30-day mortality (10.3% vs. 6.2%, p < 0.001, adjusted HR [95% CI] = 1.22 [1.06–1.38], p = 0.007). Conclusions. Among STEMI patients being treated with the most updated standard of care for primary percutaneous coronary intervention, female sex is still associated with higher complexity and impaired prognosis, displaying suboptimal epicardial reperfusion and increased in-hospital and 30-day mortality.


  • Very late-onset pacemaker pocket infection presenting as a giant granulomatous mass

    by Oğuz Kağan Şentürk, Berat Uğuz, İsMet Zengin, Tufan Günay, İlKen Uğuz

    Pacemaker-related infections are most commonly observed during the early postoperative period; however, in rare instances, they may present many years after device implantation. We report an unusual case of a giant granulomatous pacemaker pocket infection occurring 10 years after the initial implantation. The patient presented with localized inflammatory signs without systemic manifestations. Following surgical removal of the device and the associated mass, histopathological examination confirmed xanthogranulomatous inflammation. Staphylococcus epidermidis was isolated from tissue cultures. Complete device extraction combined with prolonged antimicrobial therapy resulted in full clinical resolution, followed by successful contralateral re-implantation. This case highlights the importance of maintaining long-term vigilance in patients with cardiac implantable electronic devices.

  • Open Access

    Is There a Predictive Value of the Frontal QRS-T Angle for Spinal Anesthesia-Induced Hypotension in Cesarean Delivery?

    by Ilken Uğuz, Serra Topal, Berat Uğuz

    Objective: This study aimed to investigate the potential role of frontal QRS-T (fQRS-T) angle in predictingspinal anesthesia-induced hypotension (SAIH) in parturients undergoing elective cesarean section. Methods: A total of 120 parturients undergoing elective cesarean section under spinal anesthesia were included in the study. They were divided into two groups based on the development of SAIH (SAIH group, n = 91; no-hypotension group, n = 29). Patient characteristics, laboratory findings, fQRS-T angle, and other ECG parameters before and after spinal anesthesia were evaluated across the study groups. Results: Overall, 91 (75.8%) of the 120 patients developed SAIH, and ephedrine was administered to 76 (83.5%) of them. The fQRS-T angle and other ECG parameters did not show significant differences between the SAIH and no-hypotension groups. In the SAIH group, no significant differences in the fQRS-T angle were noted in relation to ephedrine usage or dose. No significant differences were observed between the two groups regarding age, BMI, comorbidity, smoking status, ASA classification, obstetric history, or laboratory findings. The fQRS-T angle did not correlate with maternal age, weight, or BMI, irrespective of the development of SAIH. Conclusions: Our findings indicate that the fQRS-T angle is not significantly associated with the likelihood of developing SAIH in parturients undergoing elective cesarean section or with the use and dosage of ephedrine in those who developed SAIH. Additionally, no other parameters (e.g., age, BMI, comorbidity, smoking status, ASA classification, other ECG parameters, or blood analysis findings) were associated with the development of SAIH.

  • Open Access

    Fixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease in Turkish Population: DAPT-TR

    by Ahmet Öz, Kenan Toprak, Ertan Aydin, İbRahim Saraç, Mustafa Doğduş, Selçuk Opan, Mustafa Yenerçağ, Mustafa Begenc Tascanov, Ömer Kümet, Miraç Karaağaç, et al.

    Background Dual antiplatelet therapy (DAPT) is the treatment of choice for patients with acute and chronic coronary syndromes as it reduces mortality and prevents recurrent thrombotic complications. The assessment of both ischaemic burden and bleeding risk is crucial in deciding which DAPT to choose and how long it should be continued. Objectives The aim of our study was to perform prospective clinical follow-up of patients receiving fixed-dose combination therapy (ASA 75 mg + clopidogrel 75 mg). Our study is a multicentric, cross-sectional, observational, cohort study. Methods A total of 1500 patients who were started on fixed-dose combination DAPT for acute or chronic coronary syndrome were included in the study. Primary endpoints were hospitalization for any reason, hospitalization for cardiovascular cause, acute myocardial infarction, stent thrombosis, target vessel revascularization and bleeding; the secondary endpoints were death for any reason or cardiovascular cause and stroke. The significance level adopted in the statistical analysis was 5%. Results Median age was 63 years; 78.5% of the patients were receiving DAPT treatment for acute coronary syndrome. The rates of hospitalization for cardiovascular reasons, acute myocardial infartion, stent thrombosis and target-vessel revascularization were 7.9%, 2.3%, 1.3% and 4.2%, respectively. While the rate of BARC type 1 bleeding was 3.3%, the rate of BARC type 5, 3, or 2 bleeding was 0.6%. The secondary endpoints which were death from any cause, cardiovascular death and stroke were 0.5%, 0.3% and 0.3%, respectively. Conclusion: Our study shows that fixed-dose combination therapy is effective and safe in appropriately selected patients with acute or chronic coronary syndromes.


  • Prevalence of Fabry Disease in patients with left ventricular hypertrophy in Turkey: Multicenter study (LVH-TR subgroup analysis)

    by Tuncay Güzel, Fatma Nihan Turhan Çağlar, Berkay Ekici, Mehmet Kış, Selvi Öztaş, Ahmet Öz, Gülay Gök, Zeynep Kolak, Ercan Akşit, Süleyman Anıl Sarıca, et al.

    Purpose: In this prospective study we aimed to determine the rate of Fabry Disease (FD) in patients with left ventricular hypertrophy (LVH), and to evaluate the clinical presentations of patients with FD in a comprehensive manner. In addition, we aimed to raise awareness about this issue by allowing early diagnosis and treatment of FD. Methods: Our study was planned as national, multicenter, observational. Totally 22 different centers participated in this study. A total of 886 patients diagnosed with LVH by echocardiography (ECHO) were included in the study. Demographic data, biochemical parameters, electrocardiography (ECG) findings, ECHO findings, treatments and clinical findings of the patients were recorded. Dry blood samples were sent from male patients with suspected FD. The α-Gal A enzyme level was checked and genetic testing was performed in patients with low enzyme levels. Female patients suspected of FD were genetically tested with the GLA Gene Mutation Analysis. Results: FD was suspected in a total of 143 (16.13%) patients included in the study. The α-Gal-A enzyme level was found to be low in 43 (4.85%) patients whom enzyme testing was requested. GLA gene mutation analysis was positive in 14 (1.58%) patients. Male gender, E/e’ mean ,and severe hypertrophy are important risk factor for FD. Conclusion: In daily cardiology practice, FD should be kept in mind not only in adult patients with unexplained LVH but also in the entire LVH population. Dry blood test (DBS) should be considered in high-risk patients, and mutation analysis should be considered in required patients.


  • Open Access

    Age-Related Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS-STEMI COVID-19 Registry

    by Giuseppe De Luca, Magdy Algowhary, Berat Uguz, Dinaldo C. Oliveira, Vladimir Ganyukov, Oliver Busljetik, Miha Cercek, Lisette Okkels Jensen, Poay Huan Loh, Lucian Calmac, et al.

    Background: The constraints in the management of patients with ST-segment elevation myocardial infarction (STEMI) during the COVID-19 pandemic have been suggested to have severely impacted mortality levels. The aim of the current analysis is to evaluate the age-related effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI within the registry ISACS-STEMI COVID-19. Methods: This retrospective multicenter registry was performed in high-volume PPCI centers on four continents and included STEMI patients undergoing PPCI in March–June 2019 and 2020. Patients were divided according to age (< or ≥75 years). The main outcomes were the incidence and timing of PPCI, (ischemia time longer than 12 h and door-to-balloon longer than 30 min), and in-hospital or 30-day mortality. Results: We included 16,683 patients undergoing PPCI in 109 centers. In 2020, during the pandemic, there was a significant reduction in PPCI as compared to 2019 (IRR 0.843 (95%-CI: 0.825–0.861, p < 0.0001). We found a significant age-related reduction (7%, p = 0.015), with a larger effect on elderly than on younger patients. Furthermore, we observed significantly higher 30-day mortality during the pandemic period, especially among the elderly (13.6% vs. 17.9%, adjusted HR (95% CI) = 1.55 [1.24–1.93], p < 0.001) as compared to younger patients (4.8% vs. 5.7%; adjusted HR (95% CI) = 1.25 [1.05–1.49], p = 0.013), as a potential consequence of the significantly longer ischemia time observed during the pandemic. Conclusions: The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures, with a larger reduction and a longer delay to treatment among elderly patients, which may have contributed to increase in-hospital and 30-day mortality during the pandemic.


  • Open Access

    Gender Difference in the Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS-STEMI COVID-19 Registry

    by Giuseppe De Luca, Stephane Manzo-Silberman, Magdy Algowhary, Berat Uguz, Dinaldo C. Oliveira, Vladimir Ganyukov, Oliver Busljetik, Miha Cercek, Lisette Okkels, Poay Huan Loh, et al.

    Background. Several reports have demonstrated the impact of the COVID-19 pandemic on the management and outcome of patients with ST-segment elevation myocardial infarction (STEMI). The aim of the current analysis is to investigate the potential gender difference in the effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI patients within the ISACS-STEMI COVID-19 Registry. Methods. This retrospective multicenter registry was performed in high-volume primary percutaneous coronary intervention (PPCI) centers on four continents and included STEMI patients undergoing PPCIs in March–June 2019 and 2020. Patients were divided according to gender. The main outcomes were the incidence and timing of the PPCI, (ischemia time ≥ 12 h and door-to-balloon ≥ 30 min) and in-hospital or 30-day mortality. Results. We included 16683 STEMI patients undergoing PPCIs in 109 centers. In 2020 during the pandemic, there was a significant reduction in PPCIs compared to 2019 (IRR 0.843 (95% CI: 0.825–0.861, p < 0.0001). We did not find a significant gender difference in the effects of the COVID-19 pandemic on the numbers of STEMI patients, which were similarly reduced from 2019 to 2020 in both groups, or in the mortality rates. Compared to prepandemia, 30-day mortality was significantly higher during the pandemic period among female (12.1% vs. 8.7%; adjusted HR [95% CI] = 1.66 [1.31–2.11], p < 0.001) but not male patients (5.8% vs. 6.7%; adjusted HR [95% CI] = 1.14 [0.96–1.34], p = 0.12). Conclusions. The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures similarly observed in both genders. Furthermore, we observed significantly increased in-hospital and 30-day mortality rates during the pandemic only among females. Trial registration number: NCT 04412655.


  • Open Access

    Impact of Smoking Status on Mortality in STEMI Patients Undergoing Mechanical Reperfusion for STEMI: Insights from the ISACS–STEMI COVID-19 Registry

    by Giuseppe De Luca, Magdy Algowhary, Berat Uguz, Dinaldo C. Oliveira, Vladimir Ganyukov, Zan Zimbakov, Miha Cercek, Lisette Okkels Jensen, Poay Huan Loh, Lucian Calmac, et al.

    The so-called “smoking paradox”, conditioning lower mortality in smokers among STEMI patients, has seldom been addressed in the settings of modern primary PCI protocols. The ISACS–STEMI COVID-19 is a large-scale retrospective multicenter registry addressing in-hospital mortality, reperfusion, and 30-day mortality among primary PCI patients in the era of the COVID-19 pandemic. Among the 16,083 STEMI patients, 6819 (42.3%) patients were active smokers, 2099 (13.1%) previous smokers, and 7165 (44.6%) non-smokers. Despite the impaired preprocedural recanalization (p < 0.001), active smokers had a significantly better postprocedural TIMI flow compared with non-smokers (p < 0.001); this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. Active smokers had a significantly lower in-hospital (p < 0.001) and 30-day (p < 0.001) mortality compared with non-smokers and previous smokers; this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. In conclusion, in our population, active smoking was significantly associated with improved epicardial recanalization and lower in-hospital and 30-day mortality compared with previous and non-smoking history.


  • Open Access

    Real-time ultrasound elastographic features and color doppler imaging of mitral valve prolapse

    by Dursun Topal, Mehmet Erol Can, Evrim Karadağ Teki̇n, Berat Uğuz, Mehmet Fatih Kocamaz, Mehmet Emin Aslanci

    Background: The aim of this study was to investigate the elasticity of ocular structures in patients with mitral valve prolapse (MVP). Material and Methods: This prospective study included a total of 35 patients with MVP (study group) and 35 healthy volunteers (control group). The elastography value of the ratio of orbital fat- sclera (ROF/S) was measured with real-time US elastography. For each eye, central retinal artery (CRA), posterior ciliary artery (PCA), and ophthalmic artery (OA) were evaluated, respectively. Results: The mean ages of the patients in the study and the control groups were 31.77 ± 11.40 years, and 30.65 ± 7.45 years, respectively (P =0.511). Mean ROF/S were 1.95 ± 0.81 and 1.37 ± 1.06 (P=0.001) in the study groups and control, respectively. The mean RI of the OA was 0.67 ± 0.05 in the control group, 0.67 ±0.05 (0.55; 0.87) in study group. The mean RI of the PCA was 0.66 ± 0.05 in the control group, 0.68 ±0.06 in study group. . The mean RI of the CRA was 0.66 ± 0.05 in the control group, 0.66 ±0.06 in study group. The RI value was not a significant difference between control and study group (p > 0.05). Conclusion: Scleral elasticity was significantly increased in MVP patients. These could be related to ocular pathologies such as glacouma, kerataconus in MVP.